Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I

##STR00001##

as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I

##STR00001##

as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

The present invention relates to a compound of formula 1 and an organic electronic device comprising an organic semiconductor layer, wherein at least one organic semiconductor layer comprises a compound of formula (1), wherein L.sup.1 has the formula (2) and L.sup.2 has the formula (3), wherein L.sup.1 and L.sup.2 are bonded at “*” via a single bond independently to the same or different arylene groups or heteroarylenes group of Ar.sup.1; and wherein X.sup.1, X.sup.2 are independently selected from O, S and Se; Ar.sup.1 is selected from substituted or unsubstituted C.sub.20 to C.sub.52 arylene or C.sub.14 to C.sub.64 heteroarylene, wherein the substituent of the substituted C.sub.20 to C.sub.52 arylene or C.sub.14 to C.sub.64 heteroarylene are independently selected from C.sub.1 to C.sub.12 alkyl, C.sub.1 to C.sub.12 alkoxy, CN, halogen, OH, C.sub.6 to C.sub.25 aryl and C.sub.2 to C.sub.21 heteroaryl; R.sup.1, R.sup.2 are independently selected from substituted or unsubstituted C.sub.1 to C.sub.16 alkyl, wherein the substituent of substituted C.sub.1 to C.sub.16 alkyl is selected from C.sub.6 to C.sub.18 arylene or C.sub.2 to C.sub.12 heteroarylene; R.sup.3, R.sup.4 are independently selected from substituted or unsubstituted C.sub.1 to C.sub.16 alkyl, substituted or unsubstituted C.sub.6 to C.sub.18 arylene, C.sub.2 to C.sub.20 heteroarylene, wherein the substituent of substituted C.sub.1 to C.sub.16 alkyl, the substituent of the substituted C.sub.6 to C.sub.18 arylene, C.sub.2 to C.sub.20 heteroarylene are independently selected from C.sub.6 to C.sub.18 arylene or C.sub.2 to C.sub.12 heteroarylene; n is selected from 1 to 5, wherein n is an integer number.

Provided are an organic compound and an application thereof. The organic compound has a structure represented by Formula I. Through the design of a molecular structure, the organic compound has suitable HOMO and LUMO energy levels, high singlet energy level, good optoelectronic performance, a high glass transition temperature and good thermal stability, easily forms a good amorphous film, and is suitable for the machining and use of an OLED device. The organic compound, when used in the OLED device, may be used as a light-emitting layer material, an electron transport material or a hole blocking material and especially suitable for use as a host material of the light-emitting layer and can effectively improve the luminescence efficiency of the device, improve the device stability, extend lifetime, and reduce an operating voltage and energy consumption so that the OLED device has significantly improved performance such as luminescence efficiency, lifetime and energy consumption.

Provided are an organic compound and an application thereof. The organic compound has a structure represented by Formula I. Through the design of a molecular structure, the organic compound has suitable HOMO and LUMO energy levels, high singlet energy level, good optoelectronic performance, a high glass transition temperature and good thermal stability, easily forms a good amorphous film, and is suitable for the machining and use of an OLED device. The organic compound, when used in the OLED device, may be used as a light-emitting layer material, an electron transport material or a hole blocking material and especially suitable for use as a host material of the light-emitting layer and can effectively improve the luminescence efficiency of the device, improve the device stability, extend lifetime, and reduce an operating voltage and energy consumption so that the OLED device has significantly improved performance such as luminescence efficiency, lifetime and energy consumption.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

An object of the present invention is to provide a compound having a PDGF receptor kinase inhibitory activity.

Examples of the present invention may include, for example, a compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof.

##STR00001##

The compound of the present invention has an inhibitory activity against the PDGF receptor kinase. In addition, since the compound of the present invention has an inhibitory activity against the PDGF receptor kinase, it is useful as a therapeutic agent for respiratory diseases, cancers, smooth muscle proliferative diseases, vasoproliferative diseases, autoimmune/inflammatory diseases, metabolic diseases, vasoocclusive diseases, and the like.